Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 2
2005 4
2006 7
2007 15
2008 7
2009 5
2010 9
2011 10
2012 8
2013 3
2014 6
2015 4
2016 9
2017 5
2018 4
2019 1
2020 5
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 30159405

99 results
Results by year
Filters applied: . Clear all
Page 1
Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations.
Hauser K, Negron C, Albanese SK, Ray S, Steinbrecher T, Abel R, Chodera JD, Wang L. Hauser K, et al. Commun Biol. 2018;1:70. doi: 10.1038/s42003-018-0075-x. Epub 2018 Jun 13. Commun Biol. 2018. PMID: 30159405 Free PMC article.
BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R. Elias MH, et al. Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6. Leuk Res. 2014. PMID: 24456693
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M. Steinberg M. Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005. Clin Ther. 2007. PMID: 18158072 Review.
Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C. Fausel C. J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. doi: 10.18553/jmcp.2007.13.s8-a.8. J Manag Care Pharm. 2007. PMID: 17970609 Review.
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL, Ustun C, Natarajan K. Deremer DL, et al. Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. Clin Ther. 2008. PMID: 19108785 Review.
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Bagadi S, Saikia T, Pany A, Das B. Bagadi S, et al. Clin Lab. 2011;57(7-8):619-23. Clin Lab. 2011. PMID: 21888027
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Kamasani S, Akula S, Sivan SK, Manga V, Duyster J, Vudem DR, Kancha RK. Kamasani S, et al. Tumour Biol. 2017 May;39(5):1010428317701643. doi: 10.1177/1010428317701643. Tumour Biol. 2017. PMID: 28475010 Free article.
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T, Eide CA, Deininger MW. O'Hare T, et al. Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865. Expert Opin Investig Drugs. 2008. PMID: 18491988 Review.
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Shah NP, et al. J Clin Invest. 2007 Sep;117(9):2562-9. doi: 10.1172/JCI30890. J Clin Invest. 2007. PMID: 17710227 Free PMC article.
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Maekawa T, Ashihara E, Kimura S. Maekawa T, et al. Int J Clin Oncol. 2007 Oct;12(5):327-40. doi: 10.1007/s10147-007-0699-1. Epub 2007 Oct 22. Int J Clin Oncol. 2007. PMID: 17929114 Review.
99 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page